Peptide for treatment of fungal infections in cocoa

A cocoa-derived peptide with specific sequence identity is used to combat Moniliophthora and Phytophthora infections in cocoa, offering effective and sustainable antifungal activity.

WO2025088113A1PCT designated stage expired Publication Date: 2025-05-01CABOSSE NATURALS NV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2024/080220
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-26
Filing Date
2024-10-25
Publication Date
2025-05-01

AI Technical Summary

Technical Problem

Cocoa production is severely impacted by fungal infections caused by Moniliophthora and Phytophthora species, for which conventional chemical fungicides are costly and environmentally harmful, and existing antimicrobial peptides may lead to resistance and have limited spectrum activity.

Method used

A natural, recombinant, or synthetic peptide derived from the cocoa plant vicilin protein, with a length of 54 to 104 amino acids and at least 95% sequence identity to SEQ ID N°1, is used to prevent or control Moniliophthora and Phytophthora infections in cocoa plants.

Benefits of technology

The peptide exhibits strong antifungal activity against Moniliophthora and Phytophthora species, effectively treating and preventing fungal infections in cocoa plants, and is safer and more sustainable than conventional chemical fungicides.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000031_0001
    Figure IMGF000031_0001
  • Figure IMGF000032_0001
    Figure IMGF000032_0001
  • Figure IMGF000027_0001
    Figure IMGF000027_0001
Patent Text Reader

Abstract

The current invention relates to the use of a peptide or a composition comprising an effective amount of said peptide for treating, preventing or controlling a fungal infection in a Theobroma sp. plant wherein said peptide has a length of between 54 and 104 amino acids and wherein said peptide comprises an amino acid sequence having at least 95% sequence identity to SEQ ID N°1.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] PEPTIDE FOR TREATMENT OF FUNGAL INFECTIONS IN COCOA

[0002] FIELD OF THE INVENTION

[0003] The invention pertains to the technical field of antimicrobial peptides, more particularly natural plant-derived peptides, which exhibit antimicrobial activity against various fungal strains. In particular, the present invention relates to a natural, recombinant, or synthetic peptide derived from the cocoa plant vicilin protein. The invention further relates to the use of the peptide for the treatment of fungal infections in cocoa.

[0004] BACKGROUND

[0005] Cocoa (Theobroma cacao) holds paramount economic and cultural value worldwide, as it serves as the primary source of chocolate production, a beloved treat enjoyed by millions globally.

[0006] However, the sustainable cultivation of cocoa faces considerable challenges due to the impact of pathogen-induced diseases. Among the most destructive are infections caused by two fungal genera, Moniliophthora and Phytophthora, which pose significant threats to cocoa plantations.

[0007] Moniliophthora pernicosa, known to cause "witches' broom" disease, stands as one of the most notorious threats to cocoa. This disease induces the formation of abnormal, broom-like growths on cocoa trees, impeding the flow of water and nutrients and ultimately leading to the demise of infected plants. From the same genus, Moniliophthora roreri, known as "frosty pod rot", damages pods and the commercially important seeds of the cocoa trees.

[0008] Similarly, the Phytophthora genus comprises several species, that constitute important pathogens of cocoa. The disease, also called "black pod rot", is caused by Phytophthora palmivora and is identifiable by black, sunken lesions on cocoa bean pods, resulting in pod rot and premature detachment from the tree. Additionally, Phytophthora palmivora can infect cocoa beans directly, causing substantial crop losses and hampering cocoa production.

[0009] The losses produced by Moniliophthora and Phytophthora are highly variable, ranging from 10 to 100% depending on the geographical region. Conventional control methods, such as chemical fungicides, come with concerns of environmental impact and can be costly for farmers. As a result, the exploration of alternative, sustainable, and effective disease management strategies is of utmost importance.

[0010] Anti-microbial peptides (AMPs) are small, naturally occurring peptides that have broad-spectrum antimicrobial activity. AMPs are effective against several bacteria and fungi, including Moniliophthora and Phytophthora. Osmotin is a natural AMP effective against both Moniliophthora and Phytophthora (Falcao et al. 2016). Capsicum annuum antimicrobial protein 1 (CaAMPl) is a natural antimicrobial peptide proven to be effective against Phytophthora (Niu et al., 2020).

[0011] However, these AMPs were not tested in cocoa or a cocoa model system so their effectiveness in field conditions is not yet known. Moreover, prolonged and exclusive use of AMPs, including magainin and cecropin could lead to the development of resistance in the pathogens, reducing the effectiveness of the peptide over time. Additionally, they may have a limited spectrum of activity, leaving the cocoa crop vulnerable to other pathogens.

[0012] Therefore, there is a compelling need for new AMPs with different modes of action and enhanced efficacy against Phytophthora and Moniliophthora.

[0013] The current invention provides a new peptide, derived from cocoa, as a more comprehensive and sustainable strategy to combat Phytophthora and Moniliophthora infections in cocoa. The peptide is safe to use, preferably without containing aggressive chemicals, which can be toxic and environmentally harmful.

[0014] SUMMARY OF THE INVENTION

[0015] The present invention and embodiments thereof serve to provide a solution to one or more of the above-mentioned disadvantages. To this end, the present invention relates to the use of a peptide or composition comprising said peptide for preventing or controlling Moniliophthora sp. or Phytophthora sp. infections in a Theobroma sp. plant according to claim 1. More specifically, the present invention provides a peptide that has a length of between 54 and 104 amino acids and has at least 95% sequence identity to SEQ ID N°l. It has been surprisingly found that the use of the peptide, obtainable from Theobroma cacao or being recombinant or synthetic, provides antifungal activity against Moniliophthora sp. and Phytophthora sp. and may be an effective treatment in Theobroma sp. Preferred embodiments of the use of said peptide are shown in any of the claims 2 to 13.

[0016] In a second aspect, the invention relates to a method of treating, preventing or controlling a fungal infection in Theobroma sp. plants according to claim 14.

[0017] In a third aspect, the invention relates to a genetically modified Theobroma sp. plant expressing a peptide, according to claim 15 and to a method of producing the genetically modified plant, according to claim 16.

[0018] In a final aspect, the invention relates to a Theobroma sp. plant element expressing a peptide or treated with a peptide, according to claims 17 and 18.

[0019] DESCRIPTION OF FIGURES

[0020] FIG. 1 Impact of the recombinant peptides according to SEQ ID N°1 and SEQ ID N°2 and cocoa-derived extract on stem swelling of cocoa seedlings after infection with Moniliophthora perniciosa. Stem diameters were measured 30 days after infection and statistically compared with a Wilcoxon Rank Test. The recombinant peptide according to SEQ ID N°1 significantly reduced the infection (p < 0.05). n = 12 plants per treatment. The standard error is given.

[0021] FIG. 2 Impact of the recombinant peptides according to SEQ ID N°1 and SEQ ID N° 2 and cocoa-derived extract on stem swelling of cocoa seedlings after infection with Moniliophthora perniciosa. Stem diameters were measured 30 days after infection and statistically compared with a Wilcoxon Rank Test. Outliers were removed and p- values are given.

[0022] FIG. 3 Impact of the plant cocoa-derived extract and the recombinant peptide according to SEQ ID N°2 on stem swelling of MicroTom tomato after infection with Moniliophthora perniciosa. Stem diameters were measured 20 days after infection and statistically compared with a Wilcoxon Rank Test. The number of replicates and the p-values are given in the box plot.

[0023] FIG. 4 The impact of the cocoa-derived extract and the recombinant peptide according to SEQ ID N°2 on lesion formation on cocoa pods, 8 days after the infection. FIG. 4A and FIG 4B show the treatment with the cocoa-derived extract and Phytophthora palmivora spores (left) and only Phytophthora palmivora spores (right). FIG 4C shows the treatment with the recombinant peptide according to SEQ ID N°2 and Phytophthora palmivora spores (left) and only Phytophthora palmivora spores (right). The scale bar is 11 cm.

[0024] DETAILED DESCRIPTION OF THE INVENTION

[0025] The present invention concerns the use of a peptide or a composition comprising a peptide, for preventing, treating or curing fungal infections in cacao trees. Furthermore, the present invention relates to a method of treating fungal infections, to a method of genetically modifying a plant to express said peptide, and to a genetically modified plant expressing said peptide.

[0026] Unless otherwise defined, all terms used in disclosing the invention, including technical and scientific terms, have the meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. By means of further guidance, term definitions are included to better appreciate the teaching of the present invention.

[0027] As used herein, the following terms have the following meanings:

[0028] "A", "an", and "the" as used herein refer to both singular and plural referents unless the context clearly dictates otherwise. By way of example, "a compartment" refers to one or more than one compartment.

[0029] "About" as used herein refers to a measurable value such as a parameter, an amount, a temporal duration, and the like, is meant to encompass variations of + / - 20% or less, preferably + / -10% or less, more preferably + / -5% or less, even more preferably + / -1% or less, and still more preferably + / -0.1% or less of and from the specified value, in so far such variations are appropriate to perform in the disclosed invention. However, it is to be understood that the value to which the modifier "about" refers is itself also specifically disclosed.

[0030] "Comprise", "comprising", and "comprises" and "comprised of" as used herein are synonymous with "include", "including", "includes" or "contain", "containing", "contains" and are inclusive or open-ended terms that specify the presence of what follows e.g. component and do not exclude or preclude the presence of additional, non-recited components, features, element, members, steps, known in the art or disclosed therein.

[0031] Furthermore, the terms first, second, third and the like in the description and in the claims, are used for distinguishing between similar elements and not necessarily for describing a sequential or chronological order, unless specified. It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the invention described herein are capable of operation in other sequences than described or illustrated herein.

[0032] The recitation of numerical ranges by endpoints includes all numbers and fractions subsumed within that range, as well as the recited endpoints.

[0033] The expression "% by weight", "weight percent", "%wt" or "wt%", here and throughout the description unless otherwise defined, refers to the relative weight of the respective component based on the overall weight of the formulation.

[0034] Whereas the terms "one or more" or "at least one", such as one or more or at least one member(s) of a group of members, is clear per se, by means of further exemplification, the term encompasses inter alia a reference to any one of said members, or to any two or more of said members, such as, e.g., any >3, >4, >5, >6 or >7 etc. of said members, and up to all said members.

[0035] The term "peptide," as used herein, refers to any compound containing two or more amino acid residues joined by an amide bond formed from the carboxyl group of one amino acid residue and the amino group of the adjacent amino acid residue. The amino acid residues may have the L-form as well as the D-form, and may be naturally occurring or synthetic, linear as well as cyclic.

[0036] The term "therapeutically effective amount" is an amount that is effective to ameliorate a symptom of a disease. A therapeutically effective amount can be a "prophylactically effective amount" as prophylaxis can be considered therapy.

[0037] The "cocoa-derived extract", or "extract derived from cocoa", interchangeably used herein, is defined as a by-product obtained during the cocoa butter and cocoa powder separation process using an expeller. After the cocoa powder is collected in the separation process, the remaining fat-enriched mass can be further processed to remove any remaining solid parts and to obtain the cocoa butter. The resulting by- product, after the cocoa butter collection, represents the cocoa-derived extract, a mass comprising both cocoa solid particles and cocoa butter. The cocoa-derived extract may contain up to 20% fats. In a preferred embodiment, the cocoa-derived extract contains the peptide according to the invention.

[0038] Unless otherwise defined, all terms used in disclosing the invention, including technical and scientific terms, have the meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. By means of further guidance, definitions for the terms used in the description are included to better appreciate the teaching of the present invention. The terms or definitions used herein are provided solely to aid in the understanding of the invention.

[0039] Reference throughout this specification to "one embodiment" or "an embodiment" means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases "in one embodiment" or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment, but may. Furthermore, the particular features, structures or characteristics may be combined in any suitable manner, as would be apparent to a person skilled in the art from this disclosure, in one or more embodiments. Furthermore, while some embodiments described herein include some but not other features included in other embodiments, combinations of features of different embodiments are meant to be within the scope of the invention, and form different embodiments, as would be understood by those in the art. For example, in the following claims, any of the claimed embodiments can be used in any combination.

[0040] In a first aspect, the invention relates to the use of a peptide or a composition comprising an effective amount of said peptide for treating, preventing or controlling a fungal infection in a Theobroma sp. plant. By preference, said peptide has a length of between 54 and 104 amino acids and said peptide comprises an amino acid sequence having at least 95% sequence identity to SEQ ID N°l. The fungal infections are caused by Moniliophthora sp. or Phytophthora sp. In some embodiments, said peptide has between 56 and 102 amino acids.

[0041] In an embodiment of the use, as disclosed herein, the peptide has between 56 and 104 amino acids, between 60 and 104 amino acids, between 65 and 104 amino acids, between 70 and 104 amino acids, between 75 and 104 amino acids, between 80 and 104 amino acids, between 85 and 104 amino acids, between 90 and 104 amino acids, between 95 and 104 amino acids, or between 100 and 104 amino acids.

[0042] Alternatively, said peptide has between 54 and 102 amino acids, between 54 and 100 amino acids, between 54 and 95 amino acids, between 54 and 90 amino acids, between 54 and 85 amino acids, between 54 and 80 amino acids, between 54 and 75 amino acids, between 54 and 70 amino acids, between 54 and 65 amino acids or between 54 and 60 amino acids.

[0043] In yet other alternative embodiments of said use, the peptides have at least 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103 or 104 amino acids. In preferred embodiments, the peptide has 52, 100, or 102 amino acids.

[0044] In an embodiment of the use as disclosed herein, said peptide has at least 95% identity to SEQ ID N°l, SEQ ID N°2 or SEQ ID N°3 or that differs with maximally 3 amino acids from the sequence according to SEQ ID N°1 or 5 amino acids from SEQ ID N°2 or SEQ ID N°3.

[0045] Preferably, said peptide has an amino acid sequence exhibiting at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more preferably 100% sequence identity to SEQ ID N°l, SEQ ID N°2 or SEQ ID N°3.

[0046] The term "sequence identity" as used herein refers to the extent to which the sequences are identical on an amino acid-by-amino acid basis over a window of comparison. Thus, a "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical amino acid occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. A gap, i.e., a position in an alignment where a residue is present in one sequence but not in the other is regarded as a position with non-identical residues. Determining the percentage of sequence identity can be done manually, or by making use of computer programs that are available in the art. An example of a useful algorithm is PILEUP. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http: / / www.ncbi.nlm.nih.gov / ).

[0047] In another embodiment of the use as disclosed herein, said peptide has a sequence that differs with maximally 24, more preferably maximally 23, even more preferably maximally 22, even more preferably maximally 21, even more preferably maximally 20, even more preferably maximally 19, even more preferably maximally 18, even more preferably maximally 17, even more preferably maximally 16, even more preferably maximally 15, even more preferably maximally 14, even more preferably maximally 13, even more preferably maximally 12, even more preferably maximally 11, even more preferably maximally 10, even more preferably maximally 9, even more preferably maximally 8, even more preferably maximally 7, even more preferably maximally 6, even more preferably maximally 5, even more preferably maximally 4, even more preferably maximally 3, even more preferably maximally 2, even more preferably maximally 1 amino acid residues from one of the sequences SEQ ID N° 1, SEQ ID N° 2 or SEQ ID N° 3.

[0048] Alternatively, the peptide has a sequence identity according to SEQ ID N°l, SEQ ID N°2 or N°3.

[0049] In an embodiment of the use, as disclosed herein, the peptide is a vicilin-derived peptide that has at least 2 C-X1-X2-X3-C motifs in its amino acid sequence, wherein X is a natural amino acid. The cysteine residues in the motif form intramolecular disulfide linkages giving the specific three-dimensional structure of the peptide.

[0050] In an embodiment, Xi is glutamine or glutamic acid, X2is arginine, glutamine, or glycine and X3is arginine or lysine. In yet another embodiment the motif is CQRRC, CEQRC, CQGRC, or CQRKC.

[0051] In another embodiment, the peptide has 3 or 4 C-Xi-X2-X3-C motifs. In some embodiments, the C-Xi-X2-X3-C motifs are the same, while in other embodiments the C-Xi-X2-X3-C motifs are distinct. In an embodiment, the peptide has 2 identical C-Xi-X2-X3-C motifs and 2 different C-Xi-X2-X3-C motifs. In another embodiment, the peptide has 3 identical C-Xi-X2-X3-C motifs and 1 different C-Xi-X2-X3-C motif.

[0052] Amino acid sequence variants of a peptide contemplated herein may be substitutional, insertional, or deletion variants. Deletion variants lack one or more residues of the peptide which may not be critical for function. Substitutional variants typically contain an alternative amino acid at one or more sites within the peptide and may be designed to modulate one or more properties of the polypeptide such as stability against proteolytic cleavage.

[0053] In some embodiments the substitutions are conservative, that is, one amino acid is replaced with one of similar size and side-chain or functional group. Conservative substitutions are well known in the art and include, for example, the changes of alanine to glycine, valine, or leucine; arginine to lysine; asparagine to glutamine; aspartate to glutamate; cysteine to methionine; glutamine to asparagine; glutamate to aspartate; glycine to proline; histidine to glutamine, tyrosine, arginine, lysine, asparagine or cysteine; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine; tryptophan to phenylalanine; tyrosine to tryptophan or phenylalanine; and valine to isoleucine or leucine.

[0054] In other embodiments, the substitutions are non-conservative, that is the replacement of an amino acid with one that is chemically dissimilar.

[0055] In yet other embodiments the mutations may be missense mutations, nonsense mutations, silent mutations or frameshift mutations.

[0056] By preference, the peptide for use according to the invention is derived from or isolated from Theobroma cacao. More in particular, said peptide of the invention is derived from the N-terminal region of the vicilin protein of Theobroma cacao. Vicilin is a storage protein present and characterized in several plant species such as, but not limited to, Ananas comosus, Arachis hypogaea, Beta vulgaris, Capsicum annuum, Capsicum chinense, Carya illinoinensis, Chenopodium quinoa, Corchorus olitorius, Cucurbita maxima, Fragaria vesca, Glycine max, Gossipum arboreum, Herrania umbratica, Hordeum vulgare, Jatropha curcas, Juglans regia, Macadamia integrifolia, Macleaya cordata, Musa acuminata, Papaver somniferum, Ricinus communis, Solanum lycopersicum, Spinacia oleracea, Stenocarpus sinuatus, Theobroma cacao and Zea mays. Such proteins are typically containing an extremely hydrophilic N-proximal region. Additionally, they are produced carrying a hydrophobic N-terminal signal peptide, which is usually removed during protein maturation. The N-proximal region of said precursor protein is particularly interesting as it contains at least two, preferably four pairs of cysteine motifs (CXXXC) with the same spacing pattern. In a further embodiment of the use as disclosed herein, the peptide is derived from Theobroma cacao variety CCN-51. Surprisingly, the cacao variety CCN-51, known as highly resistant towards microbial infestations, was shown to be particularly rich in vicilin-derived N-terminal peptides.

[0057] In the embodiments where the peptides are isolated from cocoa beans, any protein isolation method known in the art may be employed.

[0058] In an embodiment, the cocoa beans are crushed, the shells are removed and the nibs are pressed in an expeller. Thereby, a mixture of butter and cocoa-derived extract is obtained. Said cocoa-derived extract is used for peptide extraction in some embodiments. Said cocoa-derived extract comprises peptides according to SEQ ID N°2 in a broad range of concentrations. In some embodiments the cocoa-derived extract comprises at least 1% peptides according to SEQ ID N°2, preferably at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 99% peptides according to SEQ ID N°2.

[0059] In another or further embodiment, said peptide is fused to a signal peptide at its N terminus. Preferably, said signal peptide has a sequence according to SEQ ID N° 4. In another embodiment, said signal peptide exhibits at least 95%, 96%, 97%, 98%, 99% or more preferably 100% sequence identity to SEQ ID N° 4. Alternatively, said peptide is fused to a signal peptide sequence that differs with maximally 3, more preferably maximally 2, and even more preferably 1 amino acid residues from the sequence SEQ ID N° 4. Vicilin proteins isolated from natural sources do not typically have said signal peptide. It has been surprisingly found that when a signal peptide was added to the peptide, its antimicrobial activity was enhanced.

[0060] In another embodiment, the peptide is a recombinant or a synthetic peptide. A suitable expression system, such as Escherichia coli, Pichia pastoris or another suitable system known in the art, upon insertion of a vector containing a coding sequence for a peptide with an SEQ ID N°l, SEQ ID N°2 or SEQ ID N°3, gives rise to a peptide. Any suitable protein / peptide synthesis method known in the art can be employed to synthesize the peptide of the invention.

[0061] In a further or another embodiment, the peptide as described herein is provided with an affinity tag at its N and / or C terminus. Affinity tags are used for affinity purification of recombinant proteins and peptides expressed in Escherichia coli and other systems. Said tag can be a poly-histidine-tag, which is an amino acid motif that consists of at least six histidine (His) residues.

[0062] Alternatively and without being limitative, the peptide can be tagged with an HQ tag that alternates histidine and glutamine residues(HQHQHQ), an HN tag that alternates histidine and asparagine (HNHNHNHNHNHN), a HAT tag (KDHLIHNVHKEEHAHAHNK), an ALFA tag (SRLEEELRRRLTE), an Avi tag (GLNDIFEAQKIEWHE), a C-tag (EPEA), a Calmodulin-tag (KRRWKKNFIAVSAANRFKKISSSGAL), a polyglutamate tag, a polyarginine tag, an E- tag (GAPVPYPDPLEPR), a FLAG-tag (DYKDDDDK), an HA-tag (YPYDVPDYA), a Myc- tag (EQKLISEEDL), a NE-tag (TKENPRSNQEESYDDNES), a Rho1 D4 tag (TETSQVAPA), an S-tag (KETAAAKFERQHMDS), an SBP tag (DEKTTGWRGGHWEGLAGELEQLRARLEHHPQGQREP) or a Strep-tag (WSHPQFEK).

[0063] The inventors have unexpectedly observed that the peptide has strong antifungal activity particularly when used for treating cacao plants against Moniliophthora sp. or Phytophthora sp. The antimicrobial peptide per se has a particular three- dimensional structure which may be determined using X-ray crystallography or nuclear magnetic resonance techniques. Without wishing to be bound to theory, it is believed that this structure plays a role in the observed activity of said peptide. Alpha-helical plant-derived antimicrobial peptides (AMPs), to which the peptide of the invention belongs, often have amphipathic helices with one face of the helix predominantly hydrophilic and the other face predominantly hydrophobic. This structure is regularly found in AMPs that disrupt cell membranes to cause leakage of the cell content and lysis and in AMPs that enter the cells to attack other structures within the cell. Alpha-helical AMPs are usually structurally disordered in solution, which facilitates passage of the dense net of the cell wall. Upon binding to the cell membrane that is hydrophobic and charged below the lipid heads, secondary structures (alpha-helices) are formed which enables the protein to penetrate the cell membrane. This order / disorder transition is predominantly regulated by the length of the hydrophobic domain within the alpha-helices. Too long hydrophobic helices lead to ordered structures in solution which has a negative impact on AMP activity.

[0064] In an embodiment, as disclosed herein, the peptide or the composition comprising said peptide is effective against a Moniliophthora species selected from Moniliophthora roreri, Moniliophthora pernicosa, Moniliophthora lusitanica, Moniliophthora thielavioides, Moniliophthora rufa, Moniliophthora fructigena, Moniliophthora hondurensis, Moniliophthora colombiana, Moniliophthora mayombensis, Moniliophthora chalciporana, Moniliophthora peregrina. The peptide or the composition comprising said peptide is preferably effective against Moniliophthora roreri or Moniliophthora pernicosa.

[0065] Moniliophthora perniciosa is a fungal pathogen that causes a devastating disease in cocoa known as "witches' broom disease." It is a significant threat to cocoa production in several regions, particularly in parts of Central and South America. The disease is characterized by the formation of abnormal, broom-like clusters of shoots and branches on the cocoa tree, hence the name "witches' broom." Moniliophthora perniciosa infects various parts of the tree, including the branches, leaves, and pods. It can lead to reduced yields, poor bean quality, and even the death of infected trees. The fungus spreads through spores that are carried by wind, rain, insects, or contaminated tools and equipment. Managing Moniliophthora in cocoa can be challenging, and control strategies often involve a combination of approaches.

[0066] Moniliophthora roreri is the causal agent of a disease known as "frosty pod rot" (also called Moniliophthora pod rot) and is considered a major threat to cocoa production in Central and South America. Frosty pod rot is characterized by the development of whitish, powdery spore masses on infected cocoa pods, which give them a frosty appearance. The disease primarily affects the pods and can cause significant yield losses and a decrease in bean quality. It can spread rapidly through spores and can be devastating to cocoa plantations if left unmanaged.

[0067] Surprisingly, the peptide of the invention is highly effective in treating Moniliophthora roreri and Moniliophthora pernicosa in Theobroma sp.

[0068] While the peptide is mainly used for treating infections of Moniliophthora in Theobroma sp., it will for instance be obvious that treatment of other plant species susceptible to Moniliophthora infections is equally within the scope of the current invention. To this end, the peptide may be used for treating Moniliophthora infections in Herrania spp. or Solanaceae species including Capsicum annum (pepper) and Solanum lycopersicon (tomato).

[0069] In an embodiment of the use, as disclosed herein, the peptide or the composition comprising said peptide is effective against a Phytophthora species selected from Phytophthora palmivora, Phytophthora capsici, Phytophthora megakarya, Phytophthora nicotianae, Phytophthora cactorum, Phytophthora cinnamomic, Phytophthora citrophthora, Phytophthora cryptogea, Phytophthora drechsleri, Phytophthora syringae, Phytophthora hibernalis, Phytophthora sojae, Phytophthora brassicae, Phytophthora infestans or Phytophthora erythroseptica. The peptide or the composition comprising said peptide is preferably effective against Phytophthora palmivora, Phytophthora capsici or Phytophthora megakarya.

[0070] Phytophthora sp. causes the black pod or pod rot in cocoa plants, contributing to up to 30% pod losses and killing up to 10% of trees annually. The disease spreads through spores, which can be dispersed by wind, rain, or contact with contaminated tools and plant material. Phytophthora infections in cocoa can be challenging, and a combination of strategies is often necessary for effective control. Phytophthora species responsible for the black pod disease include Phytophthora palmivora, Phytophthora megakarya, and Phytophthora capsica against which the peptide of the invention is effective.

[0071] It is however obvious that the peptide or composition comprising said peptide may be used against any Moniliophthora or Phytophthora species or race that induces diseases in Theobroma sp.

[0072] In an embodiment of the use, as disclosed herein, the peptide or the composition comprising said peptide is effective in treating, preventing or controlling a fungal infection in Theobroma cacao, Theobroma bicolor, Theobroma grandiforum, Theobroma gileri or Theobroma speciosum. The peptide or the composition comprising said peptide is preferably used in Theobroma cacao. While the main species used for cacao and chocolate production is Theobroma cacao, other species are also employed. Theobroma bicolor, also known as the macambo tree or macambo cacao, is found in the Amazon rainforest and is known for its large, football-shaped fruits. The seeds of Theobroma bicolor are used to produce a type of chocolate known as "white cacao" due to the light color of its beans. While it is not as widely cultivated or utilized as Theobroma cacao, it has some cultural and local importance in Brazil, Colombia, Ecuador and Peru and is affected by Moniliophthora pernicosa.

[0073] Theobroma grandiflorum, commonly known as cupuagu, is native to the Amazon rainforest in South America, particularly Brazil. The white pulp of the cupuagu has a taste described as a mix of chocolate and pineapple and is frequently used in desserts, juices and sweets. Chocolate made from cupuagu is very similar to that made from cocoa. Cupuagu trees are often incorporated in agroforestry systems throughout the Amazon due to their high tolerance of infertile soils, however, the plants are highly susceptible to Moniliophthora.

[0074] Theobroma speciosum is an evergreen tree native to the Amazon rainforest, particularly Bolivia, Brazil, Peru and Venezuela. The seeds of Theobroma speciosum are used to make chocolate and are also used to make cocoa butter substitutes.

[0075] In an embodiment of the use as disclosed herein, said peptide is formulated in a composition comprising an agriculturally compatible carrier. Said "agricultural compatible carrier" or "agricultural compatible excipient" which can be regarded as a vehicle, is generally inert and must be acceptable in agriculture. Thus, the phrase "agriculturally compatible" denotes a substance that can be used routinely under field conditions without interfering with growers' planting equipment, and without adversely influencing crop development or the desired ecological balance in a cultivated area.

[0076] The agriculturally compatible carriers or excipients can be solid. Solid carriers or excipients can include but are not limited to clays, natural or synthetic silicates, silica, resins, waxes, solid fertilizers, a polymer, a granular mass, perlite, a perlite granule, peat, a peat pellet, soil, vermiculite, charcoal, sugar factory carbonation press mud, rice husk, carboxymethyl cellulose, fine sand, calcium carbonate, flour, alum, a starch, talc, polyvinyl pyrrolidone, or a combination thereof. The agriculturally compatible carrier or excipient can be a liquid. Liquid carriers or excipients can include but are not limited to water, alcohols, ketones, petroleum fractions, oils, aromatic or paraffinic hydrocarbons, chlorinated hydrocarbons, liquefied gases or a combination thereof. More particularly, the agriculturally compatible carriers or excipients can include a dispersant, a surfactant, an additive, a thickener, an anti-caking agent, residue breakdown, a composting formulation, a granular application, diatomaceous earth, a colouring agent, a stabilizer, a preservative, a polymer, a coating or a combination thereof. A person skilled in the art can readily determine the appropriate carrier or excipient to be used taking into consideration factors such as a particular compound, plant to which the inoculum is to be applied, type of soil, climate conditions, whether the inoculum is in liquid, solid or powder form, and the like. The additive can comprise an oil, a gum, a resin, a clay, a polyoxyethylene glycol, a terpene, a viscid organic, a fatty acid ester, a sulfated alcohol, an alkyl sulfonate, a petroleum sulfonate, an alcohol sulfate, a sodium alkyl butane diamate, a polyester of sodium thiobutant dioate, a benzene acetonitrile derivative, a proteinaceous material, or a combination thereof. The proteinaceous material can include a milk product, wheat flour, soybean meal, blood, albumin, gelatin, or a combination thereof. The thickener can comprise a long chain alkylsulfonate of polyethylene glycol, polyoxyethylene oleate or a combination thereof. The surfactant can contain a heavy petroleum oil, a heavy petroleum distillate, a polyol fatty acid ester, a polyethoxylated fatty acid ester, an aryl alkyl polyoxyethylene glycol, an alkyl amine acetate, an alkyl aryl sulfonate, a polyhydric alcohol, an alkyl phosphate, or a combination thereof. The anti-caking agent can include a sodium salt such as a sodium sulfite, a sodium sulfate, a sodium salt of monomethyl naphthalene sulfonate, or a combination thereof; or a calcium salt such as calcium carbonate, diatomaceous earth, or a combination thereof.

[0077] In an embodiment, said compositions further comprise one or more of the following : water, other nutritive substance, weak acid, vegetable oil, essential oil, metabolism stimulant, emulsifying agent, viscosity agent, tinting material, suspending agent, dispersion agent, preservative, complexing agent, stabilizer, carrier, vehicle or wetting agent, or any combination thereof. In an embodiment, said compositions further comprise at least one oil, surfactant and polymer.

[0078] The compositions may be manufactured in a conventional manner. In certain embodiments, the compositions provided herein include one or more preservatives to inhibit microbial activity. Suitable preservatives include mercury-containing substances such as merfen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide, and cetylpyridinium chloride.

[0079] In an embodiment of the use as disclosed herein, the composition comprising the peptide is in a liquid, semisolid, solid or gaseous form and / or wherein said composition is in a dosage form of powder, granulate, coating, aerosol, paste, suspension, emulsion or solution. Non-limiting examples of said compositions are soluble powders, soluble granules, wettable granules, tablet formulations, dry flowables, aqueous flowables, wettable dispersible granules, oil dispersions, suspension concentrates, dispersible concentrates, emulsifiable concentrates, aqueous suspensions, fertilizer granule, or sprayable compositions. In other embodiment, said compositions are formulated to allow coating of one or more objects, spraying, spray coating, evaporating, nebulising, atomising, suspending, diluting, etc. The peptide as described herein can be formulated in the compositions at an amount of between 10 and 300 g / L, between 10 and 290 g / L, between 10 and 280 g / L, between 10 and 270 g / L, between 10 and 260 g / L, between 10 and 250 g / L, between 10 and 240 g / L, between 10 and 230 g / L, between 10 and 220 g / L, between 10 and 210 g / L, between 10 and 200 g / L, between 10 and 190 g / L, between 10 and 180 g / L, between 10 and 170 g / L, between 10 and 160 g / L, between 10 and 150 g / L, between 10 and 140 g / L, between 10 and 130 g / L, between 10 and 120 g / L, between 10 and 110 g / L, between 10 and 100 g / L, between 10 and 90 g / L, between 10 and 80 g / L, between 10 and 70 g / L, between 10 and 60 g / L, between 10 and 50 g / L, between 10 and 40 g / L, between 10 and 30 g / L, or between 10 and 20 g / L and all ranges and sub-ranges in between.

[0080] In an alternative embodiment the peptide can be formulated in the compositions at an amount of between 20 and 300 g / L, between 30 and 300 g / L, between 40 and 300 g / L, between 50 and 300 g / L, between 60 and 300 g / L, between 70 and 300 g / L, between 80 and 300 g / L, between 90 and 300 g / L, between 100 and 300 g / L, between 110 and 300 g / L, between 120 and 300 g / L, between 130 and 300 g / L, between 140 and 300 g / L, between 150 and 300 g / L, between 0 and 300 g / L, between 170 and 300 g / L, between 180 and 300 g / L, between 190 and 300 g / L, between 200 and 300 g / L, between 210 and 300 g / L, between 220 and 300 g / L, between 230 and 300 g / L, between 240 and 300 g / L, between 250 and 300 g / L, between 260 and 300 g / L, between 270 and 300 g / L, between 280 and 300 g / L, or between 290 and 300 g / L and all ranges and sub-ranges in between.

[0081] In another embodiment, the compositions contain at least 0.1% by weight of the peptide, more preferably at least 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%,

[0082] 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%,

[0083] 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%,

[0084] 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%,

[0085] 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%,

[0086] 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,

[0087] 94%, 95%, 96%, 97%, 98%, 99% or 99.5% by weight of peptide.

[0088] In an embodiment, of the use as disclosed herein, the peptide is administered to a plant or parts of said plant at a dosage of between 50 and 1500 g / ha, between 50 and 1400 g / ha, between 50 and 1400 g / ha, between 50 and 1300 g / ha, between 50 and 1200 g / ha, between 50 and 1100 g / ha, between 50 and 1000 g / ha, between 50 and 950 g / ha, between 50 and 900 g / ha, between 50 and 850 g / ha, between 50 and 800 g / ha, between 50 and 750 g / ha, between 50 and 700 g / ha, between 50 and 650 g / ha, between 50 and 600 g / ha, between 50 and 550 g / ha, between 50 and 500 g / ha, between 50 and 450 g / ha, between 50 and 400 g / ha, between 50 and 350 g / ha, between 50 and 300 g / ha, between 50 and 250 g / ha, between 50 and 200 g / ha, between 50 and 150 g / ha, or between 50 and 100 g / ha. In a preferred embodiment, the peptide is administered to a plant or parts of said plant at a dosage of between 10 and 1500 g / ha.

[0089] Alternatively, the peptide is administered to a plant or parts of said plant at a dosage of between 100 and 1500 g / ha, between 150 and 1500 g / ha, between 200 and 1500 g / ha, between 250 and 1500 g / ha, between 300 and 1500 g / ha, between 350 and 1500 g / ha, between 400 and 1500 g / ha, between 450 and 1500 g / ha, between 500 and 1500 g / ha, between 550 and 1500 g / ha, between 600 and 1500 g / ha, between 650 and 1500 g / ha, between 700 and 1500 g / ha, between 750 and 1500 g / ha, between 800 and 1500 g / ha, between 850 and 1500 g / ha, between 900 and 1500 g / ha, between 950 and 1500 g / ha, between 1000 and 1500 g / ha, between 1100 and 1500 g / ha, between 1200 and 1500 g / ha, between 1300 and 1500 g / ha, or between 1400 and 1500 g / ha.

[0090] In an embodiment of the use, as disclosed herein, the composition comprising the peptide comprises further antifungal agents. None-limiting examples of such further antifungal agents include Ridomil Gold®, Timorex Gold®, propiconazole, mancozeb, thiabendazole, copper-based fungicides (e.g., copper oxychloride, copper hydroxide), difenoconazole, azoxystrobin, tridemorph, tebuconazole, carbendazim, prochloraz, chlorothalonil, flutriafol, metalaxyl, captan, cyproconazole, thiophanate- methyl, fluazinam, boscalid, pyraclostrobin, metalaxyl-m, cyazofamid, propamocarb, famoxadone, phosphorous acid, dimethomorph, cymoxanil, fludioxonil, trifloxystrobin, mandipropamid, or azoxystrobin.

[0091] In a second aspect, the current disclosure relates to a method of treating, preventing or controlling a fungal infection in a Theobroma sp. plant, by means of administering a peptide or a composition comprising an effective amount of said peptide having a length of between 54 and 104 amino acids and comprising an amino acid sequence having at least 95% sequence identity to SEQ ID N°l, to a plant, a plant part or a substrate comprising or hosting said plant thereby conferring pathogen resistance or pathogen control to said plant. In embodiments of the method, as disclosed herein, the length and the sequence identity of the peptide are as disclosed in any of the previous embodiments. In further embodiments of the method, as disclosed herein, the peptide has a sequence identity according to SEQ ID N°l, SEQ ID N°2 or SEQ ID N°3 as disclosed in any of the previous embodiments. In yet a further embodiment of the method as disclosed herein, the peptide is derived from the plant species and / or varieties as disclosed in previous embodiments. In some embodiments of the method, the peptide is fused to a signal peptide as disclosed in any of the previous embodiments.

[0092] The method as disclosed herein, may be applied for treating cacao plants against Moniliophthora sp. or Phytophthora sp. pathogens, as disclosed in the previous embodiments. In a further embodiment, the method as disclosed herein may be applied for treating the Theobroma plant species disclosed in the previous embodiments.

[0093] In a further embodiment of the method disclosed herein, the peptide is formulated into a composition that comprises an agriculturally compatible carrier as disclosed in the previous embodiments. The composition may be in any of the forms described in the previous embodiment and may be formulated at the concentrations disclosed in the previous embodiments. In yet a further embodiment of the method, the peptide or the composition comprising said peptide is applied to a plant or plant part at the dosages disclosed in the previous embodiments. In a further embodiment of the method, the composition may comprise a further antifungal agent as disclosed in any of the previous embodiments.

[0094] In a third aspect, the current disclosure related to a genetically modified Theobroma sp. plant expressing a peptide wherein said peptide has a length of between 54 and 104 amino acids and comprises an amino acid sequence having at least 95% sequence identity to SEQ ID N°l.

[0095] In other embodiments of the genetically modified Theobroma sp. plant, the peptide has a length as disclosed in the previous embodiments, has a sequence identity as disclosed in the previous embodiments and / or has a sequence identity according to SEQ ID N°l, SEQ ID N°2 or SEQ ID N°3 as disclosed in any of the previous embodiments.

[0096] In a fourth aspect, the current disclosure relates to a method of producing a genetically modified Theobroma sp. plant comprising a peptide as disclosed in any of the previous embodiments, wherein said method comprises the step of introducing a nucleic acid encoding for said peptide into a plant cell thereby producing a genetically modified plant cell expressing said peptide and regenerating the genetically modified plant cell into a genetically modified plant.

[0097] The method comprises the steps of:

[0098] (a) optionally isolating or synthesizing a nucleic acid sequence encoding a peptide exhibiting at least 95% sequence identity to SEQ ID N° 1, SEQ ID N° 2 or SEQ ID N° 3 or that differs with maximally 3 amino acids from the sequence according to SEQ ID N° 1 or 5 amino acids from SEQ ID N° 2 or SEQ ID N°3.; and incorporating the nucleic acid sequence into a suitable expression vector;

[0099] (b) introducing the nucleic acid into at least a plant cell by a genetic modification method to produce a transformed plant cell expressing said peptide;

[0100] (c) regenerating the genetically modified plant cell into whole genetically modified plants; and

[0101] (d) selecting and identifying genetically modified plants expressing said peptide using suitable screening methods.

[0102] In an embodiment of the method, as disclosed herein, the nucleic acid sequence encoding for the peptide is isolated using any method known in the art, such as gene cloning methods. Non-limiting examples of gene cloning include PCR-based cloning and restriction enzyme-based cloning.

[0103] In another embodiment of the method disclosed herein, the DNA sequence of the peptides is introduced into the plant cell by biolistic bombardment. Biolistic bombardment involves introducing foreign DNA sequences into plant cells using a gene gun. The DNA sequence encoding the antimicrobial peptide as disclosed herein is attached to metal particles, such as gold particles, and then bombarded into the plant cells.

[0104] In yet another embodiment, the DNA sequence of the peptides is introduced into the plant cell by electroporation which involves the use of electrical pulses to create pores in the cell membrane, allowing the DNA sequence encoding the antimicrobial peptide to enter said cell. Alternatively, the DNA sequence encoding the antimicrobial peptide may be directly injected into the plant cell (microinjection).

[0105] In yet another alternative embodiment the DNA sequence encoding said peptide is introduced into the plant cells by PEG-mediated transformation that involves the use of polyethylene glycol (PEG) to create temporary pores in the cell membrane, allowing the DNA sequence to enter the cell.

[0106] In yet another alternative embodiment, the DNA sequence encoding said peptide is introduced into the plant cells by Agrobacterium-mediated transformation with Agrobacterium tumefaciens or Agrobacterium rhizogenes.

[0107] In yet another embodiment, the DNA sequence encoding said peptide is introduced into the plant cells by engineered viral vectors, preferably plant viral vector systems able to infect plants, based on DNA viruses, positive-strand RNA viruses or negativestrand RNA viruses. Non-limiting examples of vectors include sonchus yellow net rhabdovirus (SYNV).

[0108] Any plant organ, tissue or explant may be used with the genetic modification method in order to obtain the genetically modified plant as disclosed herein. Non-limiting examples include individual cells, callus, seeds, leaf explants, stem explants, root explants, embryonic tissue, meristems or pollen.

[0109] Overall, the specific genetic modification method and explant used to obtain the genetically modified plant expressing the peptide as disclosed herein depend on factors such as the plant species, the efficiency of the transformation method, and the desired level of expression of the antimicrobial peptide.

[0110] In a further embodiment of the method as disclosed herein the genetically modified cell is regenerated into an entire plant expressing the peptide.

[0111] The genetically modified plants expressing the peptide are identified and selected. This step is essential for eliminating the non-modified plans. Antibiotic or herbicide resistance selection is one of the most commonly used selection methods for genetically modified plants. The genetically modified plants are transformed with a gene that confers resistance to an antibiotic or herbicide and are then grown on a medium containing said antibiotic or herbicide, which kills or inhibits the growth of the non-modified plants. In some embodiments, the genetically modified plants are transformed with a gene that encodes the reporter protein and can then be easily identified and selected based on the expression of the reporter gene.

[0112] In other embodiments, the genetically modified plants are selected by nutritional selection. This method is based on the ability of the genetically modified plants to grow on media lacking a specific nutrient that is essential for the growth of nonmodified plants. The genetically modified plants are transformed with a gene that confers the ability to synthesize the missing nutrient.

[0113] Marker-free selection involves the use of selectable markers that can be removed from the genetically modified plants after selection. This can be achieved using sitespecific recombination systems, such as the Cre-lox system, which allows for the removal of the selectable marker gene without leaving any trace of the foreign DNA.

[0114] In a final aspect, the current disclosure relates to a Theobroma sp. plant element expressing a peptide or treated with a peptide or composition comprising an effective amount of the peptide, wherein said peptide exhibits at least 95% sequence identity to SEQ ID N° 1, SEQ ID N° 2 or SEQ ID N° 3 or that differs with maximally 3 amino acids from the sequence according to SEQ ID N° 1 or 5 amino acids from SEQ ID N° 2 or SEQ ID N°3.

[0115] A "plant element" is intended to generically reference either a whole plant or a plant component, including but not limited to plant tissues, parts, and cell types. A plant element is preferably one of the following: whole plant, seedling, meristematic tissue, ground tissue, vascular tissue, dermal tissue, seed, leaf, root, shoot, stem, flower, ear, spike, spikelet, fruit, stolon, bulb, tuber, corm, keiki, or bud. As used herein, a "plant element" is synonymous with a "portion" of a plant, and refers to any part of the plant, can include distinct tissues and / or organs, and may be used interchangeably with the term "tissue" throughout. In addition, a "plant element" is intended to generically reference any part of a plant that is able to initiate other plants via either sexual or asexual reproduction of that plant, for example, but not limited to seed, seedling, root, shoot, cutting, scion, graft, stolon, bulb, tuber, corm, keikis, or bud. In a preferred embodiment, the plant element is a seed, a fruit, a pod, a flower, a leaf, a stem, a root or a cutting.

[0116] In other embodiments of the plant element, the peptide has a length or sequence identity as disclosed in the previous embodiments of this disclosure.

[0117] The present invention is in no way limited to the embodiments described and / or shown in the examples. On the contrary, the present invention may be realized in many different ways without departing from the scope of the invention. All the findings of the current disclosure relating to the use of the peptide, methods of treating, preventing or controlling infections using said peptide, methods of transforming a plant to express said peptide, plants or plant parts expressing said peptide, and / or plant parts treated with said peptide also apply to the model plant species used in the current disclosure to exemplify the invention, namely tomato.

[0118] The invention is further described by the following non-limiting examples which further illustrate the invention, and are not intended to, nor should they be interpreted to limit the scope of the invention.

[0119] EXAMPLES

[0120] Example 1: Peptide production

[0121] DNA fragments encoding for a peptide having the sequence identity of SEQ ID N° 1, 2 and 3 were ligated into the BamHl / Kpnl sites of the cloning vector pEXA128. Both the plasmid carrying the DNA of the peptide and the pQE30 overexpression plasmid were transformed into E. coli DH5o cells for amplification. The plasmids were extracted from overnight cultures, were digested with BamHI and Kpnl at 37 °C for 2 hours and were separated on 1% agarose gels. Linearized pQE30 plasmids and inserts from the pEXA128 plasmids were extracted from the gels and inserts were ligated into the pQE30 plasmid. The pQE30 overexpression plasmid encodes the HIS tag and overexpression of the peptide of the invention will give rise to a fusion peptide consisting of the peptide and an N-terminal HIS tag. The resulting plasmids were transformed into E. coli M15 overexpression cells. Plasmids that were extracted from overnight cultures were sequenced and only clones that matched the expected sequences were used for overexpression. 16 ml overnight cultures were used to inoculate 800 ml liquid LB medium at 37 °C. Once an optical density measured at 600 nm (OD6oo) of between 0.6 and 0.8 was reached, IPTG was added to a final concentration of 1 mM to induce overexpression. The cells overexpressing the peptides fused to the signal peptide were incubated for 24 hours at 20 °C, and the cells overexpressing the peptides without the signal peptide for 5 hours at 37 °C.

[0122] The peptides were purified from the E. coli cells via the HIS-Tag, followed by extraction from SDS-PAGE gels.

[0123] Example 2: Production of cocoa-derived extract

[0124] Non-fermented but well-dried Theobroma cocoa CCN-51 beans were deshelled. The deshelled nibs were transferred to an expeller to separate cocoa powder from cocoa butter, the latter still containing a brown-coloured fraction. The solid particles fraction was separated from the cocoa butter by centrifuging at 11000 rpm for 10 minutes at 40 °C. The butter fraction that collected on top and decanted, while the solid pellet comprising the cocoa-derived extract was pulverized and stored at 4°C in Falcon® tubes until further use.

[0125] Results: The cocoa-derived extract obtained contained a mixture of proteins. About 10 to 20% of said protein mixture is represented by peptides according to SEQ ID N°2.

[0126] Example 3: Cocoa bean peptide extraction and purification

[0127] A cocoa-derived extract was obtained from Theobroma cocoa CNN-51 beans according to the method described in Example 2 and used for further protein extraction and purification. The proteins were extracted either using a chemical or heat extraction method.

[0128] Chemical protein extraction

[0129] The pulverized cocoa-derived extract was pre-heated in a water bath at 50°C for 10 min and then was dissolved in a protein extraction buffer (100 mM Tris buffer, 1% SDS and 1 % DTT, pH 8.1) or in a 1% DTT in tap water solution, added in a 1:4 w / v pellet to buffer ratio. The dissolved cocoa-derived extract pellet was incubated for Ih at room temperature under agitation, followed by centrifugation at 11000 rpm for 20 min. The buffer was removed by acid precipitation of proteins with 1 M citric acid (pH 6.0). Alternatively, the buffer was removed by ultrafiltration with a 3 kDa MWCO (Centricon Plus-70, Merck Chemicals GmbH, an affiliate of Merck KGaA, Darmstadt, Germany).

[0130] Protein heat extraction

[0131] The pulverized cocoa-derived extract was mixed with tap water at a 1 :4 w / v ratio and -heated in a water bath at 60°C for 10 min, followed by centrifugation at 11000 rpm for 20 min. The water-soluble proteins were collected in the liquid phase.

[0132] Protein purification

[0133] The obtained protein mixtures were quantified via Bradford assay (Coomassie® Plus Assay Reagent, Thermo Fisher Scientific Waltham, MA USA) and SDS-PAGE to confirm the presence and / or enrichment of the peptides according to the invention. The protein extract was lyophilized for up-concentration prior to its application. The band corresponding to the peptide according to the invention was excised from an SDS-PAGE gel and purified according to Retamal et al. 1999 before being tested in minimum inhibitory concentration (MIC) assays.

[0134] In an embodiment, the peptide according to SEQ ID N°2 was isolated from cocoa beans and purified to at least 90% degree of purity. For this, proteins and peptides of the cocoa bean-derived protein heat extract were separated by SDS-PAGE, and the band corresponding to SEQ N°2 was excised from the gel, cleaned up by dialysis, lyophilized, and resuspended in distilled water reaching a purity of ~90-95% according to Retamal et al. 1999.

[0135] Example 4. Minimum inhibitory concentration (MIC) assays

[0136] MIC assays determine the lowest concentration at which a compound inhibits the growth of a microbial population. The antifungal potential of recombinant peptides having sequence identities according to SEQ ID N°1 and SEQ ID N°2, the peptide according to SEQ ID N°2 isolated from cocoa and the cocoa-derived extract was tested against Moniliophthora perniciosa biotype C in biotrophic and saprophytic phase, Moniliophthora perniciosa biotype S in saprophytic, Moniliophthora roreri, Phytophthora palmivora, Phytophthora megacarya, and Phytophthora capsici. Clotrimazole was used as the positive control.

[0137] The recombinant peptides according to SEQ ID N°1 and SEQ ID N°2 the peptide according to SEQ ID N°2 isolated from cocoa and the cocoa-derived extract were serially diluted in order to create a concentration sequence ranging from 0.39 pg / ml to 303 pg / ml.

[0138] Biotrophic phase Moniliophthora perniciosa was cultured in water agar (30 g / L agar, 20 ml / L glycerol) or in liquid growth medium (5 g / L yeast extract, 50 ml / L glycerol, 2,5 g / L K2HPO4 and 1 ml trace elements consisting of 500 mg / 100 ml FeSO4*7H2O, 156 mg / 100 ml MnSO4*H2O, 167 mg / 100 ml ZnCI2, 200 mg / 100 ml CoCI2and 1 ml / 100 ml 19 % HCL) at 25°C as described by Meinhardt, Bellato et al. 2006. The saprotrophic growth phase Moniliophthora perniciosa was cultured on potato dextrose agar.

[0139] Both growth phases were evaluated based on the number of nuclei under the microscope before the assessment of MICs (Meinhardt, Bellato et al. 2006). Moniliophthora roreri and Phytophthora megakarya were cultured on potato dextrose, whereas Phytophthora palmivora and Phytophthora capsici var. Leonian were cultured on V8-juice medium. The liquid culture medium for MICs was potato dextrose for al fungi except for Phytophthora capsici, which was cultured in maltose- peptone liquid medium.

[0140] For the MIC assay, all the fungi were grown on agar plates with their respective media. Pre-cultures were prepared by inoculating small pieces of fungi in 5 ml of the respective liquid medium. The OD6oo was measured after one to five days and adjusted to an OD6oo of 1. This cell suspension was used to prepare 1:500 dilutions, corresponding to approximately 2 x 106microbial cells per ml.

[0141] 96-well plates were prepared with the test peptides. Each well contained 100 pl microbial culture, 90 pl culture medium, and 10 pl peptide or control at the corresponding dilution. The plates were incubated overnight (ON) at 30°C. Results were visually evaluated and MICs were determined based on growth or no growth. MIC assays were conducted in at least two independent replicates.

[0142] Results: All the peptides according to the invention showed strong antifungal activity against both Moniliophthora perniciosa biotypes tested and against both growth phases of Moniliophthora. The peptides were also capable of inhibiting the growth of Moniliophthora roreri, Phytophthora palmivora, Phytophthora megacarya, and Phytophthora capsici. Nonetheless, the cocoa-derived extract was effective at a MIC concentration much higher than the recombinant peptides according to SEQ ID N° 1 and 2 and the peptide according to SEQ ID N°2 isolated from cocoa. This is attributed to the fact that the cocoa-derived extract comprises the total protein extract from the cocoa beans and thus the peptides according to the invention are diluted by other proteins in the mixture.

[0143] The recombinant peptides according to SEQ ID N°1 and 2 and the peptide according to SEQ ID N°2 isolated from cocoa were also effective in inhibiting the growth of the three Phytophthora species tested. The peptides inhibited the growth of all three Phytophthora species tested at concentrations lower than the MIC value of clotrimazole.

[0144] The MIC values obtained for the peptides according to SEQ ID N°1 and SEQ ID N°2, the peptide according to SEQ ID N°2 isolated from cocoa and the cocoa-derived extract peptides against Moniliophthora and Phytophthora are shown in Table 1. Table 1. Results of MIC assays with the peptides of the invention using different

[0145] Moniliophthora and Phytophthora. Clotrimazole was used as a reference. Example 5. Determination of the curative and preventive doses of the peptides

[0146] An in vitro experiment was set up to determine the minimum preventative and curative concentrations of the recombinant peptide according to SEQ ID N°1 and SEQ ID N°2 against Moniliophthora perniciosa C-biotype biotrophic, Moniliophthora perniciosa C-biotype saprophytic, Moniliophthora perniciosa S-biotype saprophytic, Moniliophthora roreri, Phytophthora palmivora, Phytophthora megakarya, and Phytophthora capsici.

[0147] Each condition was performed in three replicates.

[0148] To determine the preventive and curative doses of the peptides according to the invention, fungal cells were incubated at varying concentrations in the culture medium, as described in Example 3, for 24 h. Cells were recovered on Agar plates in a dilution series and the number of colony-forming units (CFU / mL) was determined after 2 days. The curative concentration was determined as the concentration, where no CFU could be recovered on agar plates while the preventive dose was determined as the MIC.

[0149] Results: The concentrations corresponding to the preventive and curative doses are depicted in Table 2. The curative doses were 1.4 to 16 times higher than the preventive doses for the recombinant peptide SEQ ID N°2, and 2 to 8 times higher for SEQ ID N°l.

[0150] Table 2. Preventive and curative doses of the peptides according to the invention, in treating Moniliophthora and Phytophthora (P. = preventive; C.=curative).

[0151] Example 6. Cocoa meristem infection by M. perniciosa

[0152] Cocoa seedlings were germinated from cocoa pods. They were grown in a Conviron G-1000 plant incubation chamber with a controlled light, temperature, and humidity regime (12 h light at 28-30°C and 12 h dark at 22-24°C, 85 % humidity). The seedlings were used in infection assays once the first leaves appeared. The tips (meristems) were infected with basidiospores of M. pernicosa C-biotype using the agar drop method. Thereby, the basidiospores were thawn at 37°C and adjusted to a spore count of 106spores / mL from which 60 pl were dropped onto the meristem immediately before the treatment. Only spore solutions with a germination rate of at least 80-90% were used. Each plant was inoculated with 60 pl spore culture in 0.3 % agar. The plants were treated at the infection site, immediately after infection, with the cocoa-derived extract comprising the peptide of the invention, and with recombinant peptides according to SEQ ID N° 1 and 2. The cocoa-derived peptide extract was applied at two doses, 20 pl of a 6.5 mg / ml stock or 200 pl of a 1 mg / ml stock. For the peptide according to SEQ ID N°l, the dosage was 20 pl of a 500 g / ml stock and the dosage for the peptide according to SEQ ID°N 2 was 20 ml of a 1970 pg / ml stock. Immediately after infection, the infected cocoa parts were covered with a plastic bag to achieve 100 % humidity for 48 h. Afterwards, the plastic bags were removed, and the plants were placed under the conditions described above. The plants were evaluated after 10, 20 and 30 days.

[0153] Results: After 30 days only 6 of the 12 infected control plants showed stem swelling. When considering the full dataset, only the recombinant peptide according to SEQ ID N°1 significantly reduced the stem swelling (FIG. 1). However, tendencies to lower stem diameters were indicated in all cases. When removing the plants that gave no visible symptoms from the control group, all treatments with the peptides significantly reduced the number of infected plants (FIG. 2) (positive control: n = 6, mean = 3.6 mm; negative control: n = 12, mean = 2.6 mm, p < 0.005; SEQ ID N°l : n = 11, mean = 2.7 mm, p < 0.005; SEQ ID N°2: n = 12, mean = 2.7 mm, p < 0.05; cocoa derived peptide extract: n = 12, mean = 2.6 mm, p < 0.05).

[0154] When calculating the ratio of stem-swelling to cured plants, the recombinant peptide according to SE ID N°1 caused a reduction of infected plants by 83.3 %, the recombinant peptide according to SEQ ID N°2 accounted for a reduction of 66.7 % and the cocoa-derived peptide extract reduced the number of infected plants by 75 % at the used concentrations. Thereby, plants with a diameter of above 3 mm were considered as showing symptoms.

[0155] Example 7 ■ MicroTom tomato infection by M. perniciosa

[0156] The investigation of the M. perniciosa x T. cacao interaction is limited by the biological characteristics of the host with respect to the long reproductive cycle. It was previously shown that MicroTom tomatoes are a reliable model system for investigating the M. perniciosa interaction with a susceptible host. (Deganello et al., 2014). To this end, MiroTom x M. perniciosa S-biotype interaction was used as a model system for T. cacao x M. perniciosa C-biotype interaction.

[0157] To further investigate the effects of the peptides according to the invention, on the treatment of M. perniciosa infections, the Solanum lycopersicon (tomato) cultivar MicroTom was used.

[0158] Shoot apexes and leaf axillary buds of 17-day-old MicroTom tomato seedlings were inoculated with 60 pL of an M. perniciosa S-biotype basidiospore suspension (105spores / mL). The plants were treated at the infection site, immediately after infection, with the cocoa-derived extract comprising the peptide of the invention and the recombinant peptide according to SEQ ID N° 2. The cocoa-derived extract was applied at two doses, 20 pl of a 6.5 mg / ml stock or 200 pl of a 1 mg / ml stock. The recombinant peptide according to SEQ ID N°2 was applied at a dosage of 20 ml of a 1970 pg / ml Stock. After inoculation, the seedlings were kept in a humid chamber for 48 h, at 12h photoperiod. After the incubation time, the plants were transferred to a growth chamber at 26°C, 60% humidity and 12h photoperiod. The experiment was set up with 5- 20 plants per treatment in a randomized manner. The diameter was evaluated after 10, 20 and 30 days with a caliper.

[0159] Results: The stem diameter of the infected tomato plants, where no preventive treatment was applied, was higher than the diameter of uninfected plants, 20 days post-infection. Both the cocoa-derived extract and the peptide according to SEQ ID N° 2 significantly reduced M. perniciosa infection in tomatoes (FIG. 3, Wilcoxon Rank test, p < 0.05).

[0160] Example 8. Cocoa pod infection by Phytophthora species

[0161] Immature cocoa pods were infected by applying onto their sterilized surface a 1x1 cm piece of sterile filter paper dipped into spores solution of Phytophthora palmivora. Water was used as a control. Shortly after the infection, the cocoa-derived extract comprising the peptides of the invention was applied at a dose of 50 pL of 5 mg / ml stock, and the recombinant peptide according to SEQ ID N°2 was applied at a dose of 20 pl of 2mg / ml stock to the filter paper. On each pod, a filter paper consisting of one of the peptide treatments, and a negative and a positive control treatment was applied. The pods were evaluated for fungal infection after 9 days at 80 % humidity and 25°C in the dark.

[0162] Results: The sections of the pods where the filter paper impregnated with both treatments corresponding to the peptides of the invention were applied, showed no symptoms of infection with Phytophthora palmivora. The recombinant peptide according to SEQ ID N°2 and the cocoa-derived extract effectively prevented infections with Phytophthora palmivora (FIG. 4)

[0163] Example 9. Cocoa leaves infection by Phytophthora species

[0164] Leaves from three-month-old cocoa seedlings are inoculated with a zoospore suspension of 1 x 107zoospores / ml in 0.4% (w / v) agar-water medium. Thereby, 1 cm2of the abaxial side of the leaf (is covered with this solution. Shortly after the infection, the cocoa-derived extract comprising the peptides of the invention and the recombinant peptide according to SEQ ID N°2 is applied at the infection site. A humidity of 80 - 100 % is maintained by covering the plant with a plastic bag. Leaves are evaluated for lesions after 96 h, based on the % lesion area of the leave.

[0165] A prevention of lesion formation is expected at the sites treated with the peptide according to the invention.

[0166] Exam MIC assays were setup using the method described in Example 4. MIC values against Phytophthora palmivora, Phytophthora megacarya, Phytophthora capsici Moniliophthora perniciosa biotype C in biotrophic and saprophytic phase, and Moniliophthora roreri, were determined for 4 peptides from which 2 peptides are according to embodiments of the invention (SEQ ID N°1 and SEQ ID N°2) and 2 are prior art peptides (SEQ ID N°25 and SEQ ID N°26). The results of the MIC tests are presented in Table 3.

[0167] Table 3. Results of MIC assays with the peptides of the invention (SEQ ID N°1 and SEQ ID N°2) and prior art peptides (SEQ ID N°25 and SEQ ID N°26) using different Moniliophthora and Phytophthora species.

[0168] Peptide of the Peptide of the Prior art Prior art invention invention peptide peptide according to according to according to according to

[0169] SEQ ID N°1 SEQ ID N°2 SEQ ID N°25 SEQ ID N°26

[0170] Phytophthora8, 5 1250 25 palmivora

[0171] Phytophthora8‘5 2.55 25 25 megakarya

[0172] Phytophthora O-2^ 1 -56 3.12 capsici M. perniciosa8‘5 7.25 16 25 biotrophic phase „ . . 8.5 0.9 6 6.25

[0173] M. perniciosa saprophytic phase M. roreri 19.25 23 50 50

[0174] The peptides according to the invention, having SEQ ID N°1 and SEQ ID N° 2 were more effective in inhibiting the growth of all 5 pathogenic species of Phytophthora and said Moniliophthora tested, as the MIC values were significantly lower compared to the peptide from the prior art having SEQ ID N°25 and SEQ ID N°26. SEQUENCES LISTING

[0175] SEQ ID N° 1 (peptide according to an embodiment of the invention)

[0176] YGRKQYERDPRQQYEQCQRRCESEATEEREQEQCEQRCEREYKEQQRQQEEELQRQ

[0177] SEQ ID N° 2 (peptide according to an embodiment of the invention)

[0178] YGRKQYERDPRQQYEQCQRRCESEATEEREQEQCEQRCEREYKEQQRQQEEELQRQYQQC

[0179] QGRCQEQQQGQREQQQCQRKCWEQYKEQERGEHENYHNHKKN

[0180] SEQ ID N° 3 (peptide according to an embodiment of the invention)

[0181] YGRKQYERDPRQQYEQCQRRCESEATEEREQEQCEQRCEREYKEQQRQQEEELQRQYQQC

[0182] QGRCQEQQQGQREQQQCQRKCWEQYKEQERGEHENYHNHK

[0183] SEQ ID N° 4 (signal peptide according to an embodiment of the invention)

[0184] MVISKSPFIVLIFSLLLSFALLCSGVSA

[0185] SEQ ID N° 5 (HQ tag)

[0186] HQHQHQ

[0187] SEQ ID N° 6 (HN tag)

[0188] HNHNHNHNHNHN

[0189] SEQ ID N° 7 (HAT tag)

[0190] KDHLIHNVHKEEHAHAHNK

[0191] SEQ ID N° 8 (ALFA tag)

[0192] SRLEEELRRRLTE

[0193] SEQ ID N° 9 (Avi tag)

[0194] GLNDIFEAQKIEWHE

[0195] SEQ ID N° 10 (C-tag)

[0196] EPEA

[0197] SEQ ID N° 11 (Calmodulin-tag)

[0198] KRRWKKNFIAVSAANRFKKISSSGAL SEQ ID N° 12 (E-tag)

[0199] GAPVPYPDPLEPR

[0200] SEQ ID N° 13 (FLAG-tag)

[0201] DYKDDDDK

[0202] SEQ ID N° 14 (HA-tag)

[0203] YPYDVPDYA

[0204] SEQ ID N° 15 (Myc-tag)

[0205] EQKLISEEDL

[0206] SEQ ID N° 16 (NE-tag)

[0207] TKENPRSNQEESYDDNES

[0208] SEQ ID N° 17 (Rho1D4 tag)

[0209] TETSQVAPA

[0210] SEQ ID N° 18 (S-tag)

[0211] KETAAAKFERQHMDS

[0212] SEQ ID N° 19 (SBP tag)

[0213] DEKTTGWRGGHWEGLAGELEQLRARLEHHPQGQREP

[0214] SEQ ID N° 20 (Strep-tag)

[0215] WSHPQFEK

[0216] SEQ ID N° 21

[0217] CQRRC

[0218] SEQ ID N° 22

[0219] CEQRC

[0220] SEQ ID N° 23

[0221] CQGRC

[0222] SEQ ID N° 24 CQRKC

[0223] SEQ ID N° 25 (prior art peptide)

[0224] YERDPRQQYEQCQRRCESEATEEREQEQCEQRCEREYKEQQRQQEEE

[0225] SEQ ID N° 26 (prior art peptide)

[0226] LQRQYQQCQGRCQEQQQGQREQQQCQRKCWEQYKEQERGEHENYHNHKKNRSEEE

[0227] EGQQR

Claims

CLAIMS1. Use of a peptide or a composition comprising an effective amount of said peptide for treating, preventing or controlling a fungal infection in a Theobroma sp. plant wherein said peptide has a length of between 54 and 104 amino acids and wherein said peptide comprises an amino acid sequence having at least 95% sequence identity to SEQ ID N°l.

2. Use of a peptide according to claim 1 wherein the fungal infection is caused by Moniliophthora sp. or Phytophthora sp.

3. Use according to claim 2, wherein said Moniliophthora sp. is chosen from Moniliophthora perniciosa or Moniliophthora roreri and / or said Phytophthora sp. is chosen from Phytophthora palmivora, Phytophthora megakarya, or Phytophthora capsici.

4. Use according to any of the claims 1 to 3, wherein said fungal infection is in Theobroma cacao.

5. Use of a peptide or a composition according to any of the claims 1 to 4, wherein said peptide has at least 95% identity to SEQ ID N°l, SEQ ID N°2 or SEQ ID N°3 or that differs with maximally 3 amino acids from the sequence according to SEQ ID N° 1 or 5 amino acids from SEQ ID N°2 or SEQ ID N°3.

6. Use of a peptide or a composition according to any of the claims 1 to 5, wherein said peptide is a peptide according to SEQ ID N° 1, N° 2, or N° 3.

7. Use of a peptide or a composition according to any of claims 1 to 6, wherein said peptide is fused to a signal peptide at its N terminus.

8. Use of a peptide or a composition according to any of the previous claims 1 to 7, wherein said signal peptide has a sequence identity of 95% to SEQ ID N°4 or has a sequence according to SEQ ID N° 4.

9. Use according to any of the previous claims 1 to 8, wherein said peptide is formulated in a composition, said composition comprising an agriculturally compatible carrier.

10. Use according to claim 9, wherein said composition is in a liquid, semisolid, solid or gaseous form and / or wherein said composition is in a dosage form of powder, granulate, coating, aerosol, paste, suspension, emulsion or solution.

11. Use according to claims 9 or 10, wherein said composition comprises further antifungal agents.

12. Use according to any of the claims 1 to 11, wherein said peptide is present in an extract derived from cocoa, said extract comprises said peptide in a concentration of at least 5% w / w.

13. Use according to any of the previous claims 1 to 12, wherein said peptide is administered to the plant or parts of said plant at a dosage of between 10 and 1500 g / ha.

14. A method of treating, preventing or controlling a fungal infection in a Theobroma sp. plant, wherein by means of administering a peptide or a composition comprising an effective amount of said peptide having a length of between 54 and 104 amino acids and comprising an amino acid sequence having at least 95% sequence identity to SEQ ID N°l, to a plant, a plant part or a substrate comprising or hosting said plan, thereby conferring pathogen resistance or pathogen control to said plant.

15. A genetically modified Theobroma sp. plant expressing a peptide wherein said peptide has a length of between 54 and 104 amino acids and comprises an amino acid sequence having at least 95% sequence identity to SEQ ID N°l.

16. A method of producing the genetically modified Theobroma sp. plant of claim 15, wherein said method comprises the step of introducing a nucleic acid encoding for said peptide into a plant cell thereby producing a genetically modified plant cell expressing said peptide and regenerating the genetically modified plant cell into a genetically modified plant.

17. A Theobroma sp. plant element expressing a peptide or treated with a peptide or composition comprising an effective amount of the peptide according to any of the claims 1 to 13.

18. The Theobroma sp. plant element treated with a peptide according to claim 17, wherein said plant element is a seed, a fruit, a pod, a flower, a leaf, a stem, a root or a cutting.

Citation Information

Patent Citations

  • Antimicrobial proteins

    WO1998027805A1

  • Cocoa polypeptides and their use in the production of cocoa and chocolate flavour

    WO2002086125A2

  • Peptide having antimicrobial activity

    WO2023217847A1

  • Peptide having antimicrobial activity

    WO2023217848A1